A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

计划入组 32 人 · 首次发布于 2026 年 3 月 23 日

Prospective Huntington At Risk Observational Study

计划入组 1,001 人 · 首次发布于 2003 年 1 月 24 日

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission, at Discharge and at Post-discharge Check-up: Quasi-experimental Clinical Uncontrolled Trial (PHAROS)

计划入组 105 人 · 首次发布于 2021 年 6 月 18 日

PHI-402

IBIO-201

IBIO-200

iBio Inc

United States

pharos university in alexandria

Egypt

Bio Pharma Services Inc

Canada

Pharos iBio's PHI-101 Demonstrates Promising Complete Response in AML Phase 1 Trial

iBio to Present Preclinical Data on First-in-Class Activin E Antibody IBIO-610 for Obesity Treatment

iBio's IBIO-610 Shows Fat-Selective Weight Loss in Non-Human Primate Study